BASEL – Novartis announced this week that Richard Francis will be stepping down as chief executive officer of Sandoz, a Novartis division, and as a member of the executive committee of Novartis on March 31. Francesco Balestrieri, currently region head Europe, Sandoz, has been appointed ad-interim CEO Sandoz. He will report to Vas Narasimhan, CEO, Novartis.
HOLZKIRCHEN— Sandoz, a Novartis division, and Pear Therapeutics, Inc., announced today the commercial launch of reSET for patients with Substance Use Disorder (SUD). reSET, the first and only FDA-authorized prescription digital therapeutic, is immediately available. Study results from a multicenter, randomized clinical trial showed that reSET, when used with outpatient therapy and contingency management, significantly improved abstinence
BASEL— Novartis today announced it has agreed to sell selected portions of its Sandoz U.S. portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, to Aurobindo Pharma USA Inc., for USD 0.9 billion of cash plus USD 0.1 billion of potential earn-outs. This transaction supports the Sandoz strategy of focusing on complex
HOLZKIRCHEN, Germany — Following Food and Drug Administration final approval, Sandoz has launched of Glatopa 40 mg/ml (glatiramer acetate injection), a multiple sclerosis medication. The Novartis division said Tuesday that Glatopa 40 mg/ml, manufactured in the United States, was developed under a collaboration pact with Momenta Pharmaceuticals Inc. The product is a fully substitutable generic version of
HOLZKIRCHEN, Germany — Sandoz aims to launch five biosimilars of major oncology and immunology biologics across key geographies by 2020. The Novartis division said Monday that the new biosimilars will emerge from “an aggressive regulatory submissions strategy” of 11 product filings that began last year and will run through 2017. Plans also call for an
NEW YORK — Sandoz has inaugurated a new era in medicine with the release of Zarxio, the first biosimilar of a biologic drug approved in the United States. The Novartis subsidiary said Thursday that Zarxio — a biosimilar of Amgen Corp.’s oncology drug Neupogen, which boosts white blood cells — would broaden access to an